Anavex Life Sciences Corp. (AVXL)

$10.3

+0.29 (+2.90%)
Rating:
Recommendation:
Buy
Symbol AVXL
Price $10.3
Beta 0.919
Volume Avg. 0.89M
Market Cap 797.313M
Shares () -
52 Week Range 7.13-28.26
1y Target Est -
DCF Unlevered AVXL DCF ->
DCF Levered AVXL LDCF ->
ROE -28.50% Sell
ROA -26.97% Sell
Operating Margin -
Debt / Equity 5.30% Neutral
P/E -
P/B 5.16 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AVXL news


Dr. Christopher Missling
Healthcare
Biotechnology
NASDAQ Global Select

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.